Can Sarepta Beat Pfizer To A Duchenne Gene Therapy Breakthrough?

New Updates Sway Sentiment Behind Sarepta

 
• By Andrew McConaghie

As rival Phase III gene therapy trials get underway, Sarepta’s product could have the edge in safety and efficacy over its rival from Pfizer, but the chance of failure remains high.

Sarepta Building 2
Sarepta's is already earning revenues from its three exon-skipping DMD drugs, but a gene therapy could represent a true breakthrough for patients and their families. • Source: Alamy

More from Business

More from Scrip